(Total Views: 533)
Posted On: 05/12/2021 11:46:18 PM
Post# of 145890
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
SARS-CoV-2 variant proof - to clarify. Lerolimab might not be effective for amino acid substitutions or INDELs in the second extracellular loop of CCR5. Other Mabs may also be SARS-CoV-2 variant proof, such as Narsoplimab, which is in I-SPY and has an FDA action date in July for TMA after HSCT.
translate?
translate?
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)